


Cat. No.: GC72874



Product Data Sheet

increase in p53 levels when compared to its effects on cells grown in the stripped medium. At a higher concentration of LY117018 (1 μ M), the level of p53 appeared to decline. Treatment with 1 μ M LY117018 resulted in a predominantly phosphorylated pRb. At lower concentrations, LY117018 did not block E2-induced pRb phosphorylation[1]. LY117018 (1 μ M; 96 hours) inhibits MCF-7 cells proliferation with an IC₅₀ of 1 μ M[2]. LY117018 suppresses oxidative stress-induced endothelial cell apoptosis through activation of ERK1/2 signaling pathway[3].

References:

- [1]. Dinda S, et al. Effects of LY117018 (a SERM analog of raloxifene) on tumor suppressor proteins and proliferation of breast cancer cells. *Horm Mol Biol Clin Investig.* 2010 Aug 1;2(1):211-7.
- [2]. Baumann KH, et al. Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro. *Breast Cancer (Auckl).* 2009 Apr 7;3:23-34.
- [3]. Yu J, et al. Raloxifene analogue LY117018 suppresses oxidative stress-induced endothelial cell apoptosis through activation of ERK1/2 signaling pathway. *Eur J Pharmacol.* 2008 Jul 28;589(1-3):32-6.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA